Author:
Verbeek Rutger,Stoekenbroek Robert M.,Hovingh G. Kees
Reference66 articles.
1. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia;Abifadel;Nat. Genet.,2003
2. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participantsin 14 randomised trials of statins;Baigent;Lancet,2005
3. Ballantyne, C. M., Neutel, J., Cropp, A., Duggan, W., Plowchalk, D.Sweeney, K., Kaila, N., Vincent, J., Bays, H., 2014. Efficacy and safety of bococizumab (RN316/PF-04950615), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in statin-treated hypercholesterolemic subjects: results from a randomized, placebo-controlled, dose-ranging study (NCT: 01592240) [abstract 1183–129]. In: Proceedings of the ACC Scientific Sessions.
4. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL)receptor and LDL cholesterol;Benjannet;J. Biol. Chem.,2004
5. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses;Benn;J. Am. Coll. Cardiol.,2010
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献